{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:35:51Z","timestamp":1793900151773,"version":"4.8.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12020-016-0984-8","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T11:06:44Z","timestamp":1463483204000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Cushing\u2019s disease: the burden of illness"],"prefix":"10.1007","volume":"56","author":[{"given":"Rosario","family":"Pivonello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"984_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ecl.2007.10.010","volume":"37","author":"R Pivonello","year":"2008","unstructured":"R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing\u2019s syndrome. Endocrinol. Metab Clin. North Am. 37, 135\u2013149 (2008)","journal-title":"Endocrinol. Metab Clin. North Am."},{"key":"984_CR2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing\u2019s syndrome. Lancet 367, 1605\u20131617 (2006)","journal-title":"Lancet"},{"key":"984_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing\u2019s disease. Endocr. Rev. 36, 385\u2013486 (2015)","journal-title":"Endocr. Rev."},{"issue":"Suppl 1","key":"984_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","volume":"92","author":"C Steffensen","year":"2010","unstructured":"C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jorgensen, Epidemiology of Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1), 1\u20135 (2010)","journal-title":"Neuroendocrinology"},{"key":"984_CR5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing\u2019s syndrome. Lancet 386, 913\u2013927 (2015)","journal-title":"Lancet"},{"key":"984_CR6","doi-asserted-by":"crossref","unstructured":"R. Pivonello, A.M. Isidori, M.C. De Martino et al., Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016 (in press)","DOI":"10.1016\/S2213-8587(16)00086-3"},{"key":"984_CR7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"E. Valassi, A. Santos, M. Yaneva et al., The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165, 383\u2013392 (2011)","journal-title":"Eur. J. Endocrinol."},{"key":"984_CR8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling et al., Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR9","first-page":"647","volume":"19","author":"J Newell-Price","year":"1998","unstructured":"J. Newell-Price, P. Trainer, M. Besser, A. Grossman, The diagnosis and differential diagnosis of Cushing\u2019s syndrome and pseudo-Cushing\u2019s states. Endocr. Rev. 19, 647\u2013672 (1998)","journal-title":"Endocr. Rev."},{"key":"984_CR10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling et al., The diagnosis of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526\u20131540 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"J. Etxabe, J.A. Vazquez, Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin. Endocrinol. (Oxf) 40, 479\u2013484 (1994)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"984_CR12","first-page":"117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"J. Lindholm, S. Juul, J.O. Jorgensen et al., Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study. J. Clin. Endocrinol. Metab. 86, 117\u2013123 (2001)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejim.2011.10.013","volume":"23","author":"D Graversen","year":"2012","unstructured":"D. Graversen, P. Vestergaard, K. Stochholm, C.H. Gravholt, J.O. Jorgensen, Mortality in Cushing\u2019s syndrome: a systematic review and meta-analysis. Eur. J. Intern. Med. 23, 278\u2013282 (2012)","journal-title":"Eur. J. Intern. Med."},{"key":"984_CR14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","volume":"169","author":"G Ntali","year":"2013","unstructured":"G. Ntali, A. Asimakopoulou, T. Siamatras et al., Mortality in Cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 169, 715\u2013723 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"984_CR15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","volume":"92","author":"OM Dekkers","year":"2007","unstructured":"O.M. Dekkers, N.R. Biermasz, A.M. Pereira et al., Mortality in patients treated for Cushing\u2019s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 92, 976\u2013981 (2007)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR16","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1210\/jc.2003-032180","volume":"89","author":"GD Hammer","year":"2004","unstructured":"G.D. Hammer, J.B. Tyrrell, K.R. Lamborn et al., Transsphenoidal microsurgery for Cushing\u2019s disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 89, 6348\u20136357 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/jc.2011-2957","volume":"97","author":"ZK Hassan-Smith","year":"2012","unstructured":"Z.K. Hassan-Smith, M. Sherlock, R.C. Reulen et al., Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years. J. Clin. Endocrinol. Metab. 97, 1194\u20131201 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR18","unstructured":"R. Pivonello, P. Vitale, L. Mantovani et al., MISSION study. A worldwide epidemiological study on the mortality associated with Cushing\u2019s syndrome performed in nearly 5000 patients. 95th annual meeting of The Endocrine Society. San Francisco, CA, USA, 15\u201318 Jun abst SAT-LB-07 (2013)"},{"key":"984_CR19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jc.2012-2893","volume":"98","author":"JK Lambert","year":"2013","unstructured":"J.K. Lambert, L. Goldberg, S. Fayngold et al., Predictors of mortality and long-term outcomes in treated Cushing\u2019s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98, 1022\u20131030 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2012.01.2514","volume":"124","author":"H Prasad","year":"2012","unstructured":"H. Prasad, D.A. Ryan, M.F. Celzo, D. Stapleton, Metabolic syndrome: definition and therapeutic implications. Postgrad. Med. 124, 21\u201330 (2012)","journal-title":"Postgrad. Med."},{"issue":"Suppl 1","key":"984_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","volume":"92","author":"R Pivonello","year":"2010","unstructured":"R. Pivonello, M. De Leo, P. Vitale et al., Pathophysiology of diabetes mellitus in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1), 77\u201381 (2010)","journal-title":"Neuroendocrinology"},{"key":"984_CR22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","volume":"61","author":"T Mancini","year":"2004","unstructured":"T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing\u2019s syndrome according to 1999 WHO\/ISH guidelines. Clin. Endocrinol. (Oxf) 61, 768\u2013777 (2004)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"984_CR23","first-page":"2664","volume":"84","author":"A Colao","year":"1999","unstructured":"A. Colao, R. Pivonello, S. Spiezia et al., Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664\u20132672 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR24","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"A. Faggiano, R. Pivonello, S. Spiezia et al., Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1\u00a0year after disease remission. J. Clin. Endocrinol. Metab. 88, 2527\u20132533 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR25","first-page":"439","volume":"67","author":"RM Gomez","year":"2007","unstructured":"R.M. Gomez, N.M. Albiger, A.G. Diaz et al., Effect of hypercortisolism control on high blood pressure in Cushing\u2019s syndrome. Medicina (B Aires) 67, 439\u2013444 (2007)","journal-title":"Medicina (B Aires)"},{"key":"984_CR26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4158\/EP12247.OR","volume":"19","author":"AL Espinosa-de-los-Monteros","year":"2013","unstructured":"A.L. Espinosa-de-los-Monteros, E. Sosa, N. Martinez, M. Mercado, Persistence of Cushing\u2019s disease symptoms and comorbidities after surgical cure: a long-term, integral evaluation. Endocr. Pract. 19, 252\u2013258 (2013)","journal-title":"Endocr. Pract."},{"issue":"Suppl 1","key":"984_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000314298","volume":"92","author":"G Kaltsas","year":"2010","unstructured":"G. Kaltsas, P. Makras, Skeletal diseases in Cushing\u2019s syndrome: osteoporosis versus arthropathy. Neuroendocrinology 92(Suppl 1), 60\u201364 (2010)","journal-title":"Neuroendocrinology"},{"key":"984_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1015362822901","volume":"4","author":"A Faggiano","year":"2001","unstructured":"A. Faggiano, R. Pivonello, M. Filippella et al., Spine abnormalities and damage in patients cured from Cushing\u2019s disease. Pituitary 4, 153\u2013161 (2001)","journal-title":"Pituitary"},{"key":"984_CR29","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1359\/jbmr.090505","volume":"24","author":"MJ Barahona","year":"2009","unstructured":"M.J. Barahona, N. Sucunza, E. Resmini et al., Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing\u2019s syndrome. J. Bone Miner. Res. 24, 1841\u20131846 (2009)","journal-title":"J. Bone Miner. Res."},{"key":"984_CR30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","volume":"58","author":"C Somma di","year":"2003","unstructured":"C. di Somma, R. Pivonello, S. Loche et al., Effect of 2\u00a0years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing\u2019s disease: a prospective study. Clin. Endocrinol. (Oxf) 58, 302\u2013308 (2003)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"984_CR31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1096-2867(97)80026-6","volume":"12","author":"LA Cohn","year":"1997","unstructured":"L.A. Cohn, Glucocorticosteroids as immunosuppressive agents. Semin. Vet. Med. Surg. (Small Anim) 12, 150\u2013156 (1997)","journal-title":"Semin. Vet. Med. Surg. (Small Anim)"},{"key":"984_CR32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg, M. Karin, Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286\u2013290 (1995)","journal-title":"Science"},{"key":"984_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","volume":"270","author":"RI Scheinman","year":"1995","unstructured":"R.I. Scheinman, P.C. Cogswell, A.K. Lofquist, A.S. Baldwin Jr, Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270, 283\u2013286 (1995)","journal-title":"Science"},{"key":"984_CR34","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","volume":"362","author":"MS Lionakis","year":"2003","unstructured":"M.S. Lionakis, D.P. Kontoyiannis, Glucocorticoids and invasive fungal infections. Lancet 362, 1828\u20131838 (2003)","journal-title":"Lancet"},{"key":"984_CR35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.idc.2007.06.001","volume":"21","author":"GG Fareau","year":"2007","unstructured":"G.G. Fareau, R. Vassilopoulou-Sellin, Hypercortisolemia and infection. Infect. Dis. Clin. North Am. 21, 639\u2013657 (2007)","journal-title":"Infect. Dis. Clin. North Am."},{"key":"984_CR36","first-page":"42","volume":"85","author":"NJ Sarlis","year":"2000","unstructured":"N.J. Sarlis, S.J. Chanock, L.K. Nieman, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J. Clin. Endocrinol. Metab. 85, 42\u201347 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF03350337","volume":"21","author":"RC Bakker","year":"1998","unstructured":"R.C. Bakker, P.R. Gallas, J.A. Romijn, W.M. Wiersinga, Cushing\u2019s syndrome complicated by multiple opportunistic infections. J. Endocrinol. Invest. 21, 329\u2013333 (1998)","journal-title":"J. Endocrinol. Invest."},{"key":"984_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnins.2015.00129","volume":"9","author":"R Pivonello","year":"2015","unstructured":"R. Pivonello, C. Simeoli, M.C. De Martino et al., Neuropsychiatric disorders in Cushing\u2019s syndrome. Front. Neurosci. 9, 129 (2015)","journal-title":"Front. Neurosci."},{"key":"984_CR39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000029054","volume":"31","author":"N Sonino","year":"1998","unstructured":"N. Sonino, G.A. Fava, A.R. Raffi, M. Boscaro, F. Fallo, Clinical correlates of major depression in Cushing\u2019s disease. Psychopathology 31, 302\u2013306 (1998)","journal-title":"Psychopathology"},{"key":"984_CR40","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1210\/jc.2010-0512","volume":"95","author":"J Tiemensma","year":"2010","unstructured":"J. Tiemensma, N.R. Biermasz, H.A. Middelkoop et al., Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 95, E129\u2013E141 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000338408","volume":"97","author":"C Dimopoulou","year":"2013","unstructured":"C. Dimopoulou, M. Ising, H. Pfister et al., Increased prevalence of anxiety-associated personality traits in patients with Cushing\u2019s disease: a cross-sectional study. Neuroendocrinology 97, 139\u2013145 (2013)","journal-title":"Neuroendocrinology"},{"key":"984_CR42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(03)12588-3","volume":"361","author":"AA Kasperlik-Zaluska","year":"2003","unstructured":"A.A. Kasperlik-Zaluska, J. Slowinska-Srzednicka, W. Zgliczynski, A woman who gained weight and became schizophrenic. Lancet 361, 705 (2003)","journal-title":"Lancet"},{"key":"984_CR43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/HYPERTENSIONAHA.108.121640","volume":"52","author":"E Singer","year":"2008","unstructured":"E. Singer, S. Strohm, U. Gobel et al., Cushing\u2019s disease, hypertension, and other sequels. Hypertension 52, 1001\u20131005 (2008)","journal-title":"Hypertension"},{"key":"984_CR44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0006-3223(99)00203-6","volume":"46","author":"MN Starkman","year":"1999","unstructured":"M.N. Starkman, B. Giordani, S.S. Gebarski et al., Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing\u2019s disease. Biol. Psychiatry 46, 1595\u20131602 (1999)","journal-title":"Biol. Psychiatry"},{"key":"984_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0090-3019(99)00197-4","volume":"53","author":"NE Simmons","year":"2000","unstructured":"N.E. Simmons, H.M. Do, M.H. Lipper, E.R. Laws Jr, Cerebral atrophy in Cushing\u2019s disease. Surg. Neurol. 53, 72\u201376 (2000)","journal-title":"Surg. Neurol."},{"key":"984_CR46","first-page":"1949","volume":"87","author":"I Bourdeau","year":"2002","unstructured":"I. Bourdeau, C. Bard, B. Noel et al., Loss of brain volume in endogenous Cushing\u2019s syndrome and its reversibility after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 87, 1949\u20131954 (2002)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1530\/EJE-13-0471","volume":"169","author":"CD Andela","year":"2013","unstructured":"C.D. Andela, S.J. van der Werff, J.N. Pannekoek et al., Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing\u2019s disease: a case-control study. Eur. J. Endocrinol. 169, 811\u2013819 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"984_CR48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0306-4530(01)00059-2","volume":"27","author":"H Forget","year":"2002","unstructured":"H. Forget, A. Lacroix, H. Cohen, Persistent cognitive impairment following surgical treatment of Cushing\u2019s syndrome. Psychoneuroendocrinology 27, 367\u2013383 (2002)","journal-title":"Psychoneuroendocrinology"},{"key":"984_CR49","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1210\/jc.2004-2488","volume":"90","author":"DP Merke","year":"2005","unstructured":"D.P. Merke, J.N. Giedd, M.F. Keil et al., Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J. Clin. Endocrinol. Metab. 90, 2531\u20132536 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR50","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1210\/jc.2009-2032","volume":"95","author":"J Tiemensma","year":"2010","unstructured":"J. Tiemensma, N.E. Kokshoorn, N.R. Biermasz et al., Subtle cognitive impairments in patients with long-term cure of Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 95, 2699\u20132714 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR51","doi-asserted-by":"crossref","first-page":"E1640","DOI":"10.1210\/jc.2012-1945","volume":"97","author":"O Ragnarsson","year":"2012","unstructured":"O. Ragnarsson, P. Berglund, D.N. Eder, G. Johannsson, Long-term cognitive impairments and attentional deficits in patients with Cushing\u2019s disease and cortisol-producing adrenal adenoma in remission. J. Clin. Endocrinol. Metab. 97, E1640\u2013E1648 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2796.1999.00483.x","volume":"245","author":"L Pikkarainen","year":"1999","unstructured":"L. Pikkarainen, T. Sane, A. Reunanen, The survival and well-being of patients treated for Cushing\u2019s syndrome. J. Intern. Med. 245, 463\u2013468 (1999)","journal-title":"J. Intern. Med."},{"key":"984_CR53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/B:PITU.0000004798.27230.ed","volume":"6","author":"MD Johnson","year":"2003","unstructured":"M.D. Johnson, C.J. Woodburn, M.L. Vance, Quality of life in patients with a pituitary adenoma. Pituitary 6, 81\u201387 (2003)","journal-title":"Pituitary"},{"key":"984_CR54","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","volume":"158","author":"SM Webb","year":"2008","unstructured":"S.M. Webb, X. Badia, M.J. Barahona et al., Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire. Eur. J. Endocrinol. 158, 623\u2013630 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"984_CR55","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1210\/jc.2004-1375","volume":"90","author":"MO Aken van","year":"2005","unstructured":"M.O. van Aken, A.M. Pereira, N.R. Biermasz et al., Quality of life in patients after long-term biochemical cure of Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 90, 3279\u20133286 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/jc.2005-1058","volume":"91","author":"JR Lindsay","year":"2006","unstructured":"J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Long-term impaired quality of life in Cushing\u2019s syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91, 447\u2013453 (2006)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR57","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1590\/S0004-27302007000800025","volume":"51","author":"R Pivonello","year":"2007","unstructured":"R. Pivonello, M.C. De Martino, M. De Leo et al., Cushing\u2019s syndrome: aftermath of the cure. Arq. Bras. Endocrinol. Metabol. 51, 1381\u20131391 (2007)","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"984_CR58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2265.2007.03082.x","volume":"68","author":"JT Chow","year":"2008","unstructured":"J.T. Chow, G.B. Thompson, C.S. Grant et al., Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing\u2019s syndrome: a review of the Mayo Clinic experience. Clin. Endocrinol. (Oxf) 68, 513\u2013519 (2008)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"984_CR59","unstructured":"Ketoconazole HRA summary of product characteristics. 2015. http:\/\/www.medicines.org.uk\/emc\/medicine\/30077"},{"key":"984_CR60","unstructured":"Metopirone summary of product characteristics. 2015. http:\/\/www.medicines.org.uk\/emc\/medicine\/26460"},{"key":"984_CR61","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","volume":"172","author":"E Daniel","year":"2015","unstructured":"E. Daniel, J.D. Newell-Price, Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing\u2019s syndrome. Eur. J. Endocrinol. 172, R263\u2013R280 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"984_CR62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"M. Fleseriu, R. Pivonello, J. Young et al., Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease. Pituitary 19, 138\u2013148 (2016)","journal-title":"Pituitary"},{"key":"984_CR63","unstructured":"Corcept Therapeutics. Mifepristone (Korlym) prescribing information. 2012. http:\/\/www.korlym.com\/docs\/KorlymPrescribingInformation.pdf"},{"key":"984_CR64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","volume":"15","author":"HG Fein","year":"2015","unstructured":"H.G. Fein, T.B. Vaughan III, H. Kushner, D. Cram, D. Nguyen, Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC. Endocr. Disord. 15, 63 (2015)","journal-title":"BMC. Endocr. Disord."},{"key":"984_CR65","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"M. Fleseriu, B.M. Biller, J.W. Findling et al., Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 97, 2039\u20132049 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR66","first-page":"171","volume":"13","author":"NA Tritos","year":"2012","unstructured":"N.A. Tritos, B.M.K. Biller, Advances in medical therapies for Cushing\u2019s syndrome. Discov. Med. 13, 171\u2013179 (2012)","journal-title":"Discov. Med."},{"key":"984_CR67","unstructured":"Novartis Pharmaceuticals Corporation. Signifor prescribing information. 2015. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/signifor.pdf"},{"key":"984_CR68","unstructured":"Novartis Pharma AG. Signifor summary of product characteristics. 2013. http:\/\/www.signifor.com\/european-product-characteristics.jsp"},{"key":"984_CR69","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price et al., A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366, 914\u2013924 (2012)","journal-title":"N. Engl. J. Med."},{"key":"984_CR70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"R. Pivonello, S. Petersenn, J. Newell-Price et al., Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin. Endocrinol. (Oxf) 81, 408\u2013417 (2014)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"984_CR71","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","volume":"16","author":"AR Lila","year":"2010","unstructured":"A.R. Lila, R.A. Gopal, S.V. Acharya et al., Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr. Pract. 16, 968\u2013976 (2010)","journal-title":"Endocr. Pract."},{"key":"984_CR72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"R. Pivonello, M.C. De Martino, P. Cappabianca et al., The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94, 223\u2013230 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"984_CR73","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"R.A. Feelders, C. de Bruin, A.M. Pereira et al., Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N. Engl. J. Med. 362, 1846\u20131848 (2010)","journal-title":"N. Engl. J. Med."},{"key":"984_CR74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167, 311\u2013326 (2012)","journal-title":"Eur. J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-0984-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0984-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T21:57:19Z","timestamp":1559426239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-0984-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-0984-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]}}}